Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.
Conditions
Interventions
Iloperidone
Ziprasidone
+1 more
Locations
42
United States
Vanda Investigational Site
Little Rock, Arkansas, United States
Vanda Investigational Site
Anaheim, California, United States
Vanda Investigational Site
Cerritos, California, United States
Vanda Investigational Site
Garden Grove, California, United States
Vanda Investigational Site
Glendale, California, United States
Vanda Investigational Site
Los Angeles, California, United States
Start Date
November 18, 2005
Primary Completion Date
September 26, 2006
Completion Date
March 21, 2007
Last Updated
December 13, 2024
NCT06894212
NCT04226898
NCT05240976
NCT06745479
NCT07455929
NCT05304767
Lead Sponsor
Vanda Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions